The GLP-1 receptor agonist* dulaglutide may reduce the incidence of stroke, particularly ischaemic stroke, in individuals with type 2 diabetes (T2D) and cardiovascular (CV) risk factors, according to findings of an exploratory analysis of the REWIND** trial.
In the treatment of idiopathic generalized epilepsy, switching from valproate to other antiepileptic drugs due to potential childbearing issues may prove detrimental, heightening the risk of poor seizure control, as shown in a recent study.
Treatment with intravenous immunoglobulin (IVIG) offers significant pain relief in patients with painful diabetic polyneuropathy (DPN) resistant to standard therapies, without deleterious side effects, according to the results of a trial.
Higher intake of plant-based fat, in particular n-6 polyunsaturated fatty acids (PUFAs), in place of carbohydrate during midlife was associated with a reduced risk of cognitive impairment in Chinese adults in later life, according to the Singapore Chinese Health Study (SCHS).
Use of lacosamide therapy in the long-term management of adult patients with epilepsy is effective and well tolerated, yielding seizure freedom rates comparable to that achieved with controlled‐release carbamazepine (carbamazepine‐CR), as reported in a recent study.
Three anticonvulsant drugs — levetiracetam, fosphenytoin, and valproate — are equally effective in stopping life-threatening epilepsy seizures in patients who are unresponsive to benzodiazepines, thus providing affirmation for physicians that any of the three drugs can be used for treating status epilepticus, according to results from ESETT*.
Prompt treatment with tranexamic acid may reduce intracerebral haemorrhage (ICH) growth in patients with ongoing bleeding, though the timing of treatment appears to be key to improved outcomes, according to a study presented at ISC 2020.